Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest C.P.A. Stories

2011-11-29 12:11:00

WELLESLEY HILLS, Mass., Nov. 29, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale. These assets were generated by Epix Pharmaceuticals, Inc. and Amgen. AMG 277 has 57-nM functional EC50 for hS1P1 receptor and discriminates against...

2011-11-17 11:22:00

WELLESLEY HILLS, Mass., Nov. 17, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 369 discriminates against S1P3 receptor by 296-fold and that the S1P1 lead compounds, including AMG 369, will be offered December 8, 2011 in a sealed bid sale. AMG 369 has 3-nM functional EC50 for hS1P1 receptor and discriminated against S1P3 receptor by 296-fold. It displayed efficacy in a DTH...

2011-11-08 15:25:00

WELLESLEY HILLS, Mass., Nov. 8, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale. Target rationale for S1P1 agonists explained. The sphingosine-1-phosphate receptor 1 (S1P1) is one of a family of five G-protein-coupled receptors and is expressed...

2011-11-01 13:54:00

WELLESLEY HILLS, Mass., Nov. 1, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the back-up compounds and S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale. Back-up Compounds -- A total of ~640 analogs were synthesized by Epix and/or Amgen chemists to explore the SAR of several chemical series...

2011-11-01 13:43:00

In the news release, Mechanology, Inc.'s Steam Turbines, Business Offered for Sale at a Sealed Bid Sale on November 18, 2011, are Suited for Applications in Power Recovery and Power Generation Packages, issued Nov. 1, 2011 by Joseph F. Finn, Jr., C.P.A. over PR Newswire, we are advised by the company that there were numerous changes throughout the release, and a new version is being issued. The complete, corrected release follows: Mechanology, Inc.'s Steam Turbine Business Offered for Sale...

2011-11-01 11:50:00

WELLESLEY HILLS, Mass., Nov. 1, 2011 /PRNewswire/ -- Joseph F. Finn, Jr. C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP ("FWG") announced today that Mechanology Inc.'s steam turbines, business offered for sale at a sealed bid sale on November 18, 2011, are suited for applications in power recovery and power generation packages. Wasted thermal energy, in certain cases, from a diverse set of sources can be recovered and utilized to generate power and electricity. The...

2011-10-25 12:59:00

WELLESLEY HILLS, Mass., Oct. 25, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") revealed today the contractual agreements for S1P1 lead compounds, AMG 369 and AMG 277, offered December 8, 2011 in a sealed bid sale. AMG-369, AMG-277 and the six back-up compounds were discovered and/or developed as part of License Agreement between Amgen and Epix (formerly Predix) using technology that Epix licensed...

2011-10-18 10:33:00

WELLESLEY HILLS, Mass., Oct. 18, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale. S1P1 agonists are currently indicated for treatment of multiple sclerosis ("MS"). MS is the second most common cause of disability in young adults (after trauma) and affects approximately 350,000 -...

2011-10-12 12:57:00

WELLESLEY HILLS, Mass., Oct. 12, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale. Some companies with S1P modulators in development currently are: Novartis, Actelion, Lexicon, Pfizer, Ono Pharmaceuticals, Glaxo Smith Kline, Mitsubishi Tanabe Pharma, Receptos, Arena Pharmaceuticals,...

2011-10-06 14:11:00

WELLESLEY HILLS, Mass., Oct. 6, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 agonists program assets generated by Epix Pharmaceuticals, Inc. and Amgen will be offered December 8, 2011 in a sealed bid sale. S1P1 agonists are currently indicated for the treatment of multiple sclerosis. S1P1 agonists may also have significant potential in multiple other indications,...